Appendix 4: Renal impairment

Similar documents
Appendix 5: Hepatic impairment

Appendix 1: Interactions

poor solubility and poor permeability unknown whether poor BA is due to poor solubility or antiglaucoma medicine for biowaiver Not eligible

WHO Model List (revised April 2002)

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour

LIST OF ESSENTIAL MEDICINES OF RA

BACKGROUND Measuring renal function :

Biowaiver for Immediate Release Solid Oral Dosage Form: A General Overview

Carboplatin + Paclitaxel Cancer of the Cervix

M0BCore Safety Profile

WHO Model List of Essential Medicines for Children Explanatory Notes

(To be Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

EML 14 COMPLEMENTARY LIST

Gemcitabine + Cisplatin Regimen

Western Locality Shared care information ~ Azathioprine and Mercaptopurine

LIST OF PRODUCTS INJECTIONS DRY POWDER INJECTIONS & LIQUID INJECTIONS. Therapeutic Segment. S.No Name Form Pharmacope

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Cisplatin and Gemcitabine (bladder)

Oxaliplatin and Gemcitabine

PRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T

PACKAGE LEAFLET: Information for the patient FUROSEMID Tablets - 40 mg Solution for injection - 20 mg / 2 ml (Furosemide)

TIP Paclitaxel, Ifosfamide and Cisplatin

Rajasthan Medical Services Corporation Limited, Jaipur

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

Renal Excretion of Drugs

Malignant disease. Chapter 8 TABLE OF CONTENTS. BNF for Pre-reg Humza Yusuf Ibrahim

Gemcitabine, Dexamethasone and Cisplatin GDP Regimen

5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS

Cisplatin / 5-Fluorouracil for Vulval Cancer

DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

Cisplatin / Paclitaxel Gynaecological Cancer

VIP (Etoposide, Ifosfamide and Cisplatin)

Essential Medicines 15th edition (March 2007) WHO Model List (revised March 2007)

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen

WHO Model List of Essential Medicines

MESULID 100 REVISED PRODUCT INFORMATION

Spironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Cisplatin and Fluorouracil

Acute Renal Failure. Dr Kawa Ahmad

Cisplatin and Fluorouracil (palliative)

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer

Adult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

PROFESSIONAL INFORMATION

Cisplatin and Vinorelbine and radiotherapy (NSCLC)

CEDIAMATE Metformin Tablets USP 500 mg

PRODUCT INFORMATION RESONIUM A. Na m

ECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M

90-Day Generic Drug Discount List Treatment Medication Strength Dose Quantity Price Allergy/Cold&Flu Benzonatate 100mg Tablet 42 $15.

Professionalism & Service with Great Prices

Renal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November

PACKAGE LEAFLET: Information for the user. METFORMINE Film-coated tablets 500 mg, 850 mg or 1000 mg (Metformin hydrochloride)

Diabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy

SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.

PRESCRIPTION SAVINGS CLUB FLAT- PRICED GENERIC DRUG LIST (EMDEON) Effective August 20, 2014

CEPP for Diffuse Large B Cell Lymphoma (LYMWOS005/1)

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Glucophage XR is contra-indicated during breast-feeding.

104 MMWR December 17, 2004

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

EML- ANTIRETROVIRALS INTERACTIONS TABLE

PRODUCT INFORMATION Panadeine EXTRA

Chapter 5 ~ Infections

Analgesia in patients with impaired renal function Formulary Guidance

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009

Generic Drug List - Alphabetical

Syria Essential Drugs List (EDL) Priority 2014

Metformin Hydrochloride

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

Subcutaneous Rituximab with or without Ibrutinib, Maintenance Period - ENRICH Study

Cisplatin and Fluorouracil (head and neck)

Using the BNF. CWFS F1 Programme Safe Prescribing Module

patient group direction

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)

Patient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton

DRUGS, PREGNECY & NEWBORN

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

PRODUCT INFORMATION UROCIT -K. Wax matrix tablets

Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen

Eplerenon Medical Valley + Eplerenon Stada

0BCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablet 40, 80, 160, 320 mg SE/H/PSUR/0024/003 Date of FAR:

Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer

R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY. Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition.

Transcription:

Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some drugs is increased even if the renal elimination is unimpaired. 3. The tolerance to adverse effects may be impaired. 4. The efficacy of some drugs may diminish. The dosage of many drugs must be adjusted in patients with renal impairment to avoid adverse reactions and to ensure efficacy. The level of renal function below which the dose of a drug must be reduced depends on how toxic it is and whether it is eliminated entirely by renal excretion or is partly metabolized to inactive metabolites. In general, all patients with renal impairment are given a loading dose which is the same as the usual dose for a patient with normal renal function. Maintenance doses are adjusted to the clinical situation. The maintenance dose of a drug can be reduced either by reducing the individual dose leaving the normal interval between doses unchanged or by increasing the interval between doses without changing the dose. The interval extension method may provide the benefits of convenience and decreased cost, while the dose reduction method provides more constant plasma concentration. In the following table drugs are listed in alphabetical order. The table includes only drugs for which specific information is available. Many drugs should be used with caution in renal impairment but no specific advice on dose adjustment is available; it is therefore important to also refer to the individual drug entries. The recommendations are given for various levels of renal function as estimated by the glomerular filtration rate (GFR), usually measured by the creatinine clearance. The serum-creatinine concentration can be used instead as a measure of renal function but it is only a rough guide unless corrected for age, sex and weight by special nomograms. Renal impairment is usually divided into three grades: mild GFR 20 50 ml/minute or approximate serum creatinine 150 300 micromol/litre GFR 10 20 ml/minute or serum creatinine 300 700 micromol/litre GFR or serum creatinine >700 micromol/litre When using the dosage guidelines the following must be considered: Drug prescribing should be kept to a minimum. Nephrotoxic drugs should, if possible, be avoided in all patients with renal disease because the nephrotoxicity is more likely to be serious.

It is advisable to determine renal function not only before but also during the period of treatment and adjust the maintenance dose as necessary. Renal function (GFR, creatinine clearance) declines with age so that by the age of 80 it is half that in healthy young subjects. When prescribing for the elderly, assume at least a mild degree of renal impairment. Uraemic patients should be observed carefully for unexpected drug toxicity. In these patients the complexity of clinical status as well as other variables for example altered absorption, protein binding or metabolism, or liver function, and other drug therapy precludes use of fixed drug dosage and an individualized approach is required. Table of drugs to be avoided or used with caution in renal impairment Drug Degree of Impairment Comment Abacavir Severe Avoid Acetazolamide Mild Avoid; metabolic acidosis Acetylsalicylic acid Severe Avoid; sodium and water retention; deterioration in renal function; increased risk of gastrointestinal bleeding Aciclovir Mild Reduce intravenous dose Alcuronium Severe Prolonged duration of block Allopurinol Moderate 100 200 mg daily; increased toxicity; rashes Severe 100 mg on alternate days (maximum 100 mg daily) Aluminium hydroxide Severe Aluminium is absorbed and may accumulate NOTE. Absorption of aluminium from aluminium salts is increased by citrates which are contained in many effervescent preparations (such as effervescent analgesics) Amidotrizoates Mild and avoid dehydration; nephrotoxic Amiloride Mild Monitor plasma potassium; high risk of hyperkalaemia in renal impairment; amiloride excreted by kidney unchanged Amoxicillin Severe ; rashes more common Amoxicillin + Clavulanic acid Amphotericin B Mild Use only if no alternative; nephrotoxicity may be reduced with use of complexes Ampicillin Severe ; rashes more common Artemether + Lumefantrine Severe Caution; monitor ECG and plasma potassium Atenolol Moderate (excreted unchanged) Severe Start with small dose; higher plasma

concentrations after oral administration; may reduce renal blood flow and adversely affect renal function Azathioprine Severe Azithromycin Use with caution no information available Benzathine benzylpenicillin Severe Neurotoxicity high doses may cause convulsions Benzylpenicillin Severe Maximum 6 g daily; neurotoxicity high doses may cause convulsions Bleomycin Moderate Carbamazepine Manufacturer advises caution Ceftazidime Mild Ceftriaxone Severe Maximum 2 g daily; also monitor plasma concentration if both renal impairment and hepatic impairment Chlorambucil Moderate Use with caution and monitor response; increased risk of myelosuppression Chloramphenicol Severe Avoid unless no alternative; dose-related depression of haematopoiesis Chloroquine Mild to in rheumatic disease Severe for malaria prophylaxis; avoid in rheumatic disease Chlorphenamine Severe Dose reduction may be required Chlorpromazine Severe Start with small doses; increased cerebral Ciclosporin Monitor kidney function dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction (exclude rejection if kidney transplant) Ciprofloxacin Moderate Use half normal dose Cisplatin Mild Avoid if possible; nephrotoxic and neurotoxic Clindamycin Plasma half-life prolonged may need dose reduction Clonazepam Severe Start with small doses; increased cerebral Cloxacillin Severe Codeine or avoid; increased and prolonged effect; increased cerebral Colchicine Moderate Severe Avoid or reduce dose if no alternative Cyclophosphamide Dacarbazine Mild to Dose reduction may be required

Daunorubicin Severe Mild to Avoid Deferoxamine Metal complexes excreted by kidneys (in renal impairment dialysis increases rate of elimination) Diazepam Severe Start with small doses; increased cerebral Didanosine Mild ; consult manufacturer's Diethylcarbamazine ; plasma half life prolonged and urinary excretion considerably reduced Digoxin Mild ; toxicity increased by electrolyte disturbances Dimercaprol Discontinue or use with extreme caution if impairment develops during treatment Doxycycline Mild Use with caution; avoid excessive doses Efavirenz Severe No information available caution advised Eflornithine Enalapril Mild to Use with caution and monitor response; initial dose 2.5 mg once daily. Hyperkalaemia and other adverse effects more common Ephedrine Severe Avoid; increased CNS toxicity Ergometrine Severe Manufacturer advises avoid Ergotamine ; nausea and vomiting; risk of renal vasoconstriction Erythromycin Severe Maximum 1.5 g daily (ototoxicity) Ethambutol Mild ; if creatinine clearance less than 30 ml/minute monitor plasma-ethambutol concentration; optic nerve damage Fluconazole Mild to Usual initial dose then halve subsequent doses Flucytosine and monitor plasma-flucytosine concentration consult manufacturer s Fluphenazine Severe Start with small doses; increased cerebral Furosemide Moderate May need high doses; deafness may follow rapid i/v injection Gentamicin Mild ; monitor plasma concentrations; see also section 6.2.2.5 Glibenclamide Severe Avoid Haloperidol Severe Start with small doses; increased cerebral Heparin Severe Risk of bleeding increased

Hydralazine Mild if creatinine clearance less than 30 ml/minute Hydrochlorothiazide ; ineffective Ibuprofen Mild Use lowest effective dose and monitor renal function; sodium and water retention; deterioration in renal function possibly leading to renal failure Avoid Imipenem + Cilastatin Mild Insulin Severe May need dose reduction; insulin requirements fall; compensatory response to hypoglycaemia is impaired Iohexol Increased risk of nephrotoxicity; avoid dehydration Iopanoic acid Mild to Maximum 3 g Severe Avoid Isoniazid Severe Maximum 200 mg daily; peripheral neuropathy Lamivudine Mild ; consult manufacturer's Lithium Mild Avoid if possible or reduce dose and monitor plasma concentration carefully Lopinavir + Ritonavir Avoid oral solution due to propylene glycol content; use capsules with caution in impairment Magnesium hydroxide or reduce dose; increased risk of toxicity Magnesium sulfate or reduce dose; increased risk of toxicity Mannitol Avoid unless test dose produces diuretic response Meglumine see Pentavalent antimoniate antimony compounds Meglumine iotroxate Increased risk of nephrotoxicity; avoid dehydration Mercaptopurine Moderate Metformin Mild Avoid; increased risk of lactic acidosis Methotrexate Mild ; accumulates; nephrotoxic Methyldopa Moderate Start with small dose; increased to hypotensive and sedative effect Metoclopramide Severe Avoid or use small dose; increased risk of extrapyramidal reactions

Morphine Nalidixic acid Nelfinavir or avoid; increased and prolonged effect; increased cerebral Use half normal dose; ineffective in renal failure because concentration in urine is inadequate No information available manufacturer advises caution Neostigmine Moderate May need dose reduction Nitrofurantoin Mild Avoid; peripheral neuropathy; ineffective because of inadequate urine concentrations Penicillamine Mild Avoid if possible or reduce dose; nephrotoxic Pentamidine isetionate Mild ; consult manufacturer s Pentavalent antimony Moderate Increased adverse effects compounds Severe Avoid Phenobarbital Severe Avoid large doses Polyvidone iodine Severe Avoid regular application to inflamed or broken mucosa Potassium chloride routine use; high risk of hyperkalaemia Procainamide Mild Avoid or reduce dose Procaine benzylpenicillin Severe Neurotoxicity high doses may cause convulsions Procarbazine Severe Avoid Proguanil Mild 100 mg once daily Moderate 50 mg on alternate days Severe 50 mg once weekly; increased risk of haematological toxicity Propranolol Severe Start with small dose; higher plasma concentrations after oral administration; may reduce renal blood flow and adversely affect renal function Propylthiouracil Mild to Use three-quarters normal dose Severe Use half normal dose Pyridostigmine Moderate ; excreted by kidney Quinine Reduce parenteral maintenance dose for malaria treatment Ranitidine Severe Use half normal dose; occasional risk of confusion Ritonavir See Lopinavir with Ritonavir Saquinavir Severe Dose adjustment possibly required Sodium chloride Severe Avoid Sodium hydrogen Severe Avoid; specialized role in some forms of

carbonate renal disease Sodium nitroprusside prolonged use Sodium valproate see Valproic acid Spironolactone Mild Monitor plasma K + ; high risk of hyperkalaemia in renal impairment Stavudine Mild 20 mg twice daily (15 mg if body weight less than 60 kg) 20 mg once daily (15 mg if body weight less than 60 kg) Streptomycin Mild ; monitor plasma concentrations Sulfadiazine Severe Avoid; high risk of crystalluria Sulfamethoxazole + Trimethoprim Mild Use half normal dose if creatinine clearance 15 30 ml/minute; avoid if creatinine clearance less than 15 ml/minute and if plasma-sulfamethoxazole concentration cannot be monitored Sulfasalazine Moderate Risk of toxicity including crystalluria ensure high fluid intake Severe Avoid Trimethoprim Mild Use half normal dose after 3 days if creatinine clearance 15 30 ml/minute Valproic acid Mild to Severe Use half normal dose if creatinine clearance less than 15 ml/minute; avoid if creatinine clearance less than 10 ml/minute (unless plasma-trimethoprim concentration monitored) Alter dosage according to free serum valproic acid concentration Vancomycin Mild monitor plasma-vancomycin concentration and renal function regularly Vecuronium Severe ; duration of block possibly prolonged Warfarin Severe Avoid Zidovudine Severe ; manufacturer advises oral dose of 300 400 mg daily in divided doses or intravenous dose of 1 mg/kg 3 4 times daily